Differential expression of microRNAs in plasma of patients with prediabetes and newly diagnosed type 2 diabetes
- 749 Downloads
MicroRNAs (miRNAs) are present in plasma and have emerged as critical regulators of gene expression at posttranscriptional level, and thus are involved in various human diseases, including diabetes. The objective of this study was to screen and validate differentially expressed plasma miRNAs in prediabetes and newly diagnosed type 2 diabetes (T2D).
In this study, we screened differentially expressed plasma miRNAs in prediabetes and newly diagnosed T2D by miRNA microarray analysis, and validated the expression of candidate miRNAs using quantitative reverse transcription polymerase chain reaction assays. Furthermore, we performed gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses to disclose functional enrichment of genes predicted to be regulated by the differentially expressed miRNAs.
Notably, our results revealed that hsa-miR-1249, hsa-miR-320b, and hsa-miR-572 (P < 0.05) were differentially expressed among the three groups, which yielded an area under the receiver operator characteristics curve (AUC) of 0.784 [95 % confidence interval (CI) 0.685–0.883], 0.946 (95 % CI 0.906–0.985), and 0.843 (95 % CI 0.766–0.920) discriminating T2D patients from NGT control groups, respectively, while the AUC was 0.887 (95 % CI 0.818–0.957), 0.635 (95 % CI 0.525–0.744), and 0.69 (95 % CI 0.580–0.793) discriminating prediabetes patients from NGT control groups, respectively. In addition, GO and KEGG pathway analyses showed that genes predicted to be regulated by differentially expressed miRNAs were significantly enriched in several related biological processes and pathways, including the development of multicellular organisms, signal transduction, cell differentiation, apoptosis, cell metabolism, ion transport regulation, and other biological functions.
Taken together, our results showed differentially expressed miRNAs in T2D and prediabetes. Plasma hsa-miR-1249, hsa-miR-320b, and hsa-miR-572 may serve as novel biomarkers for diagnosis and potential targets for the treatment for prediabetes and T2D.
KeywordsMicroRNA Plasma Type 2 diabetes (T2D) Prediabetes Differential expression
This work was supported by Science and Technology Support Program of Guizhou Province (SY20123115 of Guizhou Branch). We thank all of the patients for agreeing to participate in our study.
Compliance with ethical standards
Conflict of interest
No conflicts of interest were declared.
All human subjects used in the study have been reviewed by the Research Ethics Committee (People’s Hospital of Guizhou Province, Guiyang, Guizhou Province, P. R. China) and have therefore been performed in accordance with the ethical standards.
Human and animal rights disclosure
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2008 (5).
Informed consent disclosure
Informed consent was obtained from all patients for being included in the study.
- 14.He C (2013) The establishment of fingerprint spectrum of circulating microRNAs in early stage diabetic nephropathy. Chongqing Medical University, Chongqing, pp 1–53Google Scholar
- 16.Jacobs ME, Jeffers LA, Welch AK, Wingo CS, Cain BD (2013) The effect of aldosterone on the miRNA content of a murine inner medullary collecting duct cell. FASEB J 27:778Google Scholar
- 32.Shi P (2013) Analysis of the expression of circulating microRNA spectral in diabetic nephropathy patients. China Medical University, Shenyang, pp 1–38Google Scholar